Brokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $7.67

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been given a consensus rating of “Reduce” by the nine research firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $7.6667.

A number of research firms have issued reports on QNCX. Lucid Cap Mkts cut Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, January 30th. Citigroup cut shares of Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, January 30th. D. Boral Capital lowered shares of Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Citizens Jmp cut shares of Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, January 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Quince Therapeutics in a research note on Monday, December 29th.

Quince Therapeutics Stock Performance

Shares of QNCX opened at $0.11 on Tuesday. Quince Therapeutics has a 52-week low of $0.09 and a 52-week high of $4.55. The firm has a market cap of $5.93 million, a price-to-earnings ratio of -0.09 and a beta of 1.28. The business’s fifty day moving average is $1.47 and its 200-day moving average is $1.97.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Quince Therapeutics during the 2nd quarter valued at $37,000. GSA Capital Partners LLP increased its holdings in Quince Therapeutics by 158.0% in the 3rd quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock worth $142,000 after purchasing an additional 53,417 shares in the last quarter. Intellectus Partners LLC acquired a new position in Quince Therapeutics in the 4th quarter worth about $179,000. Bridgeway Capital Management LLC raised its position in Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after purchasing an additional 22,200 shares during the last quarter. Finally, Hudson Bay Capital Management LP bought a new position in Quince Therapeutics in the fourth quarter valued at about $213,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.